GTF2IP7: A Potential Drug Target or Biomarker (G101927126)

Target Name: GTF2IP7

NCBI ID: G101927126

GTF2IP7

Other Name(s): General transcription factor IIi pseudogene 7 | general transcription factor IIi pseudogene 7

GTF2IP7: A Potential Drug Target or Biomarker

Gene expression is a critical process in the development and progression of many diseases, including cancer. Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences. GTF2IP7, also known as General transcription factor IIi pseudogene 7, is a gene that encodes for a protein known as GTF2IP7. This protein plays a crucial role in the regulation of gene expression and has been implicated in the development and progression of many diseases. As a result, GTF2IP7 has become a focus of interest for researchers as a potential drug target or biomarker.

History of GTF2IP7

GTF2IP7 was first identified in the late 1990s as a gene that encodes for a protein with similar sequences to known transcription factors, including GTF2, GTF3, GTF4, and GTF7. These transcription factors are known as steroid receptor coreceptor proteins (SRCPs) and are involved in the regulation of gene expression in response to steroid hormones. In contrast, GTF2IP7 is not known to have any well-established function in the regulation of gene expression.

Expression of GTF2IP7

GTF2IP7 is expressed in many tissues and cells, including brain, heart, and various types of cancer cells. It is highly expressed in the brain, with lower levels of expression found in other tissues. It is also expressed in various types of cancer, including lung, breast, and ovarian cancer.

Function of GTF2IP7

The function of GTF2IP7 is not well understood, but it is believed to play a role in the regulation of gene expression. Several studies have shown that GTF2IP7 can interact with other transcription factors, including GTF3, GTF4, and GTF7. This suggests that GTF2IP7 may be involved in the regulation of gene expression by these transcription factors.

In addition, GTF2IP7 has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and transcriptional networks. It is also involved in the regulation of various signaling pathways, including the NF-kappa pathway and the Wnt pathway.

Drug targeting GTF2IP7

GTF2IP7 has been shown to be a potential drug target in the treatment of various diseases, including cancer. Several studies have shown that inhibiting the activity of GTF2IP7 can lead to the inhibition of gene expression and the inhibition of cellular processes. This suggests that GTF2IP7 may be an effective target for the treatment of diseases that are characterized by the over-expression of gene expression, such as cancer.

Biomarker potential

GTF2IP7 has also been shown to be a potential biomarker for the diagnosis and prognosis of various diseases, including cancer. The over-expression of GTF2IP7 has been shown to be associated with the development and progression of many diseases, including cancer. As a result, GTF2IP7 may be a useful biomarker for the diagnosis and prognosis of these diseases.

Conclusion

In conclusion, GTF2IP7 is a gene that has been shown to play a critical role in the regulation of gene expression and the development and progression of many diseases. As a result, GTF2IP7 has become a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to fully understand the function of GTF2IP7 and its potential as a drug target or biomarker.

Protein Name: General Transcription Factor IIi Pseudogene 7

The "GTF2IP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF2IP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets